Detailed information regarding the testing for a normal distribution, F -test and statistical analysis results, and effect size results are summarized in Table S1
The cardiovascular outcomes trials that enrolled tens of thousands of patients with type 2 diabetesincluding LEADER (liraglutide), SUSTAIN-6 (semaglutide), REWIND (dulaglutide), and EXSCEL (exenatide ER)found no significant increase in overall cancer incidence compared to placebo over follow-up periods ranging from approximately two to five years
Chung YR, Ha KH, Lee K, Kim DJ
So far, two pills have been approved for use by the U.S
The result is that the exact same medication, from the same manufacturing facility, distributed through authorized channels, costs dramatically less simply because of where it is sold